Company Analysis SciClone Pharmaceuticals (Holdings) Limited
1. Summary
Advantages
- Price (18.72 HK$) is less than fair price (26.41 HK$)
- The stock's return over the last year (64.21%) is higher than the sector average (-14.77%).
- The company's current efficiency (ROE=35.86%) is higher than the sector average (ROE=5.19%)
Disadvantages
- Dividends (0%) are below the sector average (5.7%).
- Current debt level 21.31% has increased over 5 years from 0.0451%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| SciClone Pharmaceuticals (Holdings) Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 1.1% | 7% |
| 90 days | 0% | -27.2% | 15.5% |
| 1 year | 64.2% | -14.8% | 42.4% |
6600 vs Sector: SciClone Pharmaceuticals (Holdings) Limited has outperformed the "Healthcare" sector by 78.98% over the past year.
6600 vs Market: SciClone Pharmaceuticals (Holdings) Limited has outperformed the market by 21.84% over the past year.
Stable price: 6600 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 6600 with weekly volatility of 1.23% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (18.72 HK$) is lower than the fair price (26.41 HK$).
Price significantly below the fair price: The current price (18.72 HK$) is 41.1% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (6.85) is lower than that of the sector as a whole (35.42).
P/E vs Market: The company's P/E (6.85) is lower than that of the market as a whole (26.7).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.35) is lower than that of the sector as a whole (3.68).
P/BV vs Market: The company's P/BV (2.35) is higher than that of the market as a whole (-11.94).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.44) is lower than that of the sector as a whole (7.59).
P/S vs Market: The company's P/S indicator (2.44) is lower than that of the market as a whole (2.76).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (3.51) is higher than that of the sector as a whole (2.91).
EV/Ebitda vs Market: The company's EV/Ebitda (3.51) is lower than that of the market as a whole (9.94).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 9.77% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (9.77%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (50.73%).
5.4. ROE
ROE vs Sector: The company's ROE (35.86%) is higher than that of the sector as a whole (5.19%).
ROE vs Market: The company's ROE (35.86%) is higher than that of the market as a whole (6.28%).
5.5. ROA
ROA vs Sector: The company's ROA (26.97%) is higher than that of the sector as a whole (3.47%).
ROA vs Market: The company's ROA (26.97%) is higher than that of the market as a whole (3.38%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '5.7%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.67.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 2 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (19.17%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
